Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DR26FMDU8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $52,423
Award facts
- Contract value 100% obligated
- $52,423.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $52,423.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. This firm fixed-price delivery order, issued on October 29, 2025, with an ultimate completion date of November 20, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group will perform under its single-award Indefinite Delivery Contract (IDC) with the DLA under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical supply chains for Department of Defense healthcare operations.
DMS Pharmaceutical Group's selection reflects its established role as a critical pharmaceutical supplier within the federal military medical system, with recent substantial contracting activity through the DLA's Medical Supply Chain division. The company maintains a comprehensive product portfolio spanning branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. Under the PPV-G GEN V umbrella contract, awarded on November 13, 2025, with a $499,999,999 ceiling and completion date of December 31, 2036, the contractor operates with a 30-month base period and three 30-month option periods, positioning it to fulfill diverse pharmaceutical requirements across military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FMDU8?
SPE2DR26FMDU8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 29, 2025.
How much is contract SPE2DR26FMDU8 worth?
The government has obligated $52,423 on SPE2DR26FMDU8.
Is contract SPE2DR26FMDU8 an order under another contract?
Yes. SPE2DR26FMDU8 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDU8 competed?
The extent of competition for SPE2DR26FMDU8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award